Proton Pump Inhibitors and Risk of Acute and Chronic Kidney Disease: A Retrospective Cohort Study.
acute kidney injury
chronic kidney disease
observational study
proton pump inhibitors
Journal
Pharmacotherapy
ISSN: 1875-9114
Titre abrégé: Pharmacotherapy
Pays: United States
ID NLM: 8111305
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
pubmed:
20
2
2019
medline:
28
4
2020
entrez:
20
2
2019
Statut:
ppublish
Résumé
Proton pump inhibitors (PPIs) have been linked to acute kidney injury (AKI) and chronic kidney disease (CKD); however, current evidence has only been evaluated in a small number of studies with short follow-up periods. This study examined the association between PPI use and risk of incident AKI and CKD in a large population-based health maintenance organization (HMO) cohort. Patients aged 18 years or older, without evidence of preexisting renal disease, started on PPI therapy, and those continuously enrolled for at least 12 months between July 1993 and September 2008 were identified in an HMO database. Incidences of AKI and CKD were defined using documented International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) codes or a glomerular filtration rate less than 60 ml/min/1.73 m In 93,335 patients in the AKI cohort, 16,593 of whom were exposed to PPIs, the incidence rate of AKI was higher in the PPI group than nonusers (36.4 vs 3.54 per 1000 person-years, p<0.0001, respectively). In adjusted models, PPI exposure was associated with an increased risk of AKI (adjusted odds ratio [aOR] 4.35, 95% confidence interval [CI] 3.14-6.04, p<0.0001). In 84,600 patients in the CKD cohort, 14,514 of whom were exposed to PPIs, the incidence rate of CKD was higher in the PPI group than nonusers (34.3 vs 8.75 per 1000 person-years, p<0.0001, respectively). In adjusted models, PPIs were associated with a higher risk of CKD compared with controls (aOR 1.20, 95% CI 1.12-1.28, p<0.0001). Associations between PPI use and AKI and CKD persisted in propensity score-matched analyses. The use of PPIs is associated with an increased risk of incident AKI and CKD. This relationship could have a considerable public health impact; therefore, health care provider education and deprescribing initiatives will be necessary to raise awareness and reduce health care burden.
Sections du résumé
BACKGROUND
Proton pump inhibitors (PPIs) have been linked to acute kidney injury (AKI) and chronic kidney disease (CKD); however, current evidence has only been evaluated in a small number of studies with short follow-up periods. This study examined the association between PPI use and risk of incident AKI and CKD in a large population-based health maintenance organization (HMO) cohort.
METHODS
Patients aged 18 years or older, without evidence of preexisting renal disease, started on PPI therapy, and those continuously enrolled for at least 12 months between July 1993 and September 2008 were identified in an HMO database. Incidences of AKI and CKD were defined using documented International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) codes or a glomerular filtration rate less than 60 ml/min/1.73 m
RESULTS
In 93,335 patients in the AKI cohort, 16,593 of whom were exposed to PPIs, the incidence rate of AKI was higher in the PPI group than nonusers (36.4 vs 3.54 per 1000 person-years, p<0.0001, respectively). In adjusted models, PPI exposure was associated with an increased risk of AKI (adjusted odds ratio [aOR] 4.35, 95% confidence interval [CI] 3.14-6.04, p<0.0001). In 84,600 patients in the CKD cohort, 14,514 of whom were exposed to PPIs, the incidence rate of CKD was higher in the PPI group than nonusers (34.3 vs 8.75 per 1000 person-years, p<0.0001, respectively). In adjusted models, PPIs were associated with a higher risk of CKD compared with controls (aOR 1.20, 95% CI 1.12-1.28, p<0.0001). Associations between PPI use and AKI and CKD persisted in propensity score-matched analyses.
CONCLUSION
The use of PPIs is associated with an increased risk of incident AKI and CKD. This relationship could have a considerable public health impact; therefore, health care provider education and deprescribing initiatives will be necessary to raise awareness and reduce health care burden.
Identifiants
pubmed: 30779194
doi: 10.1002/phar.2235
pmc: PMC6453745
mid: NIHMS1012872
doi:
Substances chimiques
Proton Pump Inhibitors
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
443-453Subventions
Organisme : NCATS NIH HHS
ID : KL2 TR001413
Pays : United States
Organisme : NHLBI NIH HHS
ID : L30 HL138791
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001412
Pays : United States
Organisme : NHLBI NIH HHS
ID : 1 L30 HL138791-01
Pays : United States
Informations de copyright
© 2019 Pharmacotherapy Publications, Inc.
Références
Clin Pharmacol. 2017 May 18;9:55-64
pubmed: 28572740
Ann Fam Med. 2017 Jul;15(4):341-346
pubmed: 28694270
CMAJ. 2016 Jun 14;188(9):657-662
pubmed: 26598371
Can Fam Physician. 2017 May;63(5):354-364
pubmed: 28500192
BMJ Open. 2017 Jul 4;7(6):e015735
pubmed: 28676480
JAMA Intern Med. 2016 Feb;176(2):238-46
pubmed: 26752337
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
J Clin Gastroenterol. 2018 Jul;52(6):468-476
pubmed: 29668562
Am J Gastroenterol. 2000 Nov;95(11):3118-22
pubmed: 11095327
Kidney Int. 2012 Mar;81(5):442-8
pubmed: 22113526
Am J Epidemiol. 1989 Jan;129(1):125-37
pubmed: 2910056
Am J Gastroenterol. 2013 Mar;108(3):308-28; quiz 329
pubmed: 23419381
Curr Opin Gastroenterol. 2012 Nov;28(6):615-20
pubmed: 23010681
Postgrad Med J. 2007 Jan;83(975):66-8
pubmed: 17267683
Am Fam Physician. 2007 Oct 1;76(7):1005-12
pubmed: 17956071
Am J Gastroenterol. 2007 Sep;102(9):2047-56; quiz 2057
pubmed: 17509031
Aliment Pharmacol Ther. 2010 Jun;31(11):1165-77
pubmed: 20222914
CMAJ Open. 2015 Apr 02;3(2):E166-71
pubmed: 26389094
Expert Opin Drug Saf. 2014 Jan;13(1):57-65
pubmed: 24073682
CMAJ. 2004 Jul 6;171(1):33-8
pubmed: 15238493
Kidney Int. 2014 Oct;86(4):837-44
pubmed: 24646856
Br J Clin Pharmacol. 2007 Dec;64(6):819-23
pubmed: 17635502
J Clin Pharm Ther. 2000 Oct;25(5):333-40
pubmed: 11123484
BMC Nephrol. 2013 Jul 16;14:150
pubmed: 23865955
J Am Soc Nephrol. 2016 Oct;27(10):3153-3163
pubmed: 27080976
JAMA. 2006 Dec 27;296(24):2947-53
pubmed: 17190895
Therap Adv Gastroenterol. 2012 Jul;5(4):219-32
pubmed: 22778788
BMJ. 2008 Jan 5;336(7634):2-3
pubmed: 18174564
J Gastroenterol Hepatol. 2018 Apr 12;:
pubmed: 29644725